Boston Properties, Inc. (BXP) Tops Q4 FFO Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BXP Hot Sheet
Price: $62.10 +0.99%
Revenue Growth %: +1.8%
Financial Fact:
Gains (losses) from investments in securities: 976K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +1.8%
Financial Fact:
Gains (losses) from investments in securities: 976K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Boston Properties, Inc. (NYSE: BXP) reported Q4 FFO of $1.21, versus the analyst estimate of $1.19.
Sees Q1 2012 FFO of $1.12-$1.14, versus the consensus of $1.14.
Boston Properties, Inc. sees FY2012 FFO of $4.65-$4.78, versus the consensus of $4.76.
For earnings history and earnings-related data on Boston Properties, Inc. (BXP) click here.
Sees Q1 2012 FFO of $1.12-$1.14, versus the consensus of $1.14.
Boston Properties, Inc. sees FY2012 FFO of $4.65-$4.78, versus the consensus of $4.76.
For earnings history and earnings-related data on Boston Properties, Inc. (BXP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
